Trial reportTranslational psychiatry2026
Multi-strain probiotic intervention in adults with depressive and anxiety symptoms: A 12-Week pilot study.
Trial report in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depressive and anxiety symptoms prevalent in major depressive disorder (MDD), that affects millions globally, with many patients showing incomplete response to standard treatments. This open-label pilot study evaluated the effects of a 12-week multi-strain probiotic supplementation on depressive and anxiety symptoms in 30 adults with depressive and anxiety symptoms (e.g., MDD, adjustment disorder, anxiety disorders). Participants received a daily capsule for eight weeks containing 11 bacterial strains (9.8 billion CFU), including Bifidobacterium animalis ssp. Lactis Lafti B94 (5 billion CFU) and Lactobacillus rhamnosus RO-11 (1.9 billion CFU). Outcomes were assessed using the Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HAM-A), Generalized Anxiety Disorder 7-item scale (GAD-7), and Clinical Global Impression (CGI) scale at baseline, 4, 8, and 12 weeks following treatment. The intervention was well-tolerated, with minor gastrointestinal side effects in 10% of participants. Significant reductions were observed in HDRS (22.47 ± 6.95 to 8.83 ± 5.32, p < 0.01), HAM-A (32.27 ± 11.18 to 13.09 ± 10.49, p < 0.01), GAD-7 (15.33 ± 4.21 to 6.87 ± 5.37, p < 0.01), and CGI (4.53 ± 0.94 to 3.00 ± 1.65, p < 0.01) scores. Of note, females, participants with tertiary education, and married individuals showed greater improvements. The substantial reductions in these scores suggest probiotics may contribute in the reduction of depressive and anxiety symptoms, potentially via the microbiota-gut-brain axis, supporting further investigation in larger, controlled trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.